Oseltamivir Acid: A Benchmark Influenza Neuraminidase Inhibitor for Antiviral Research

Executive Summary: Oseltamivir acid is the active metabolite of oseltamivir and a gold-standard influenza neuraminidase inhibitor, functioning by blocking viral sialidase activity and preventing the release of progeny virions (APExBIO). It exhibits high aqueous solubility (≥46.1 mg/mL with gentle warming) and is stable at -20°C [product]. In vitro, it reduces sialidase activity and cell viability in breast cancer cell lines, with enhanced cytotoxicity when combined with standard chemotherapeutics (see Mechanistic Insights). In vivo, it inhibits tumor growth and metastasis in RAGxCγ double mutant mice at 30–50 mg/kg dosing (Yang et al., 2025). Resistance is primarily linked to the H275Y neuraminidase mutation [see detailed resistance discussion].

Biological Rationale

Oseltamivir acid (SKU: A3689) is the pharmacologically active carboxylate form derived from the ester prodrug oseltamivir, which undergoes hydrolysis by intestinal and hepatic esterases (Yang et al., 2025). This transformation enhances bioavailability and enables selective targeting of influenza virus neuraminidase, a conserved glycoprotein essential for viral particle release [APExBIO]. By inhibiting neuraminidase, Oseltamivir acid blocks the cleavage of terminal α-Neu5Ac residues from sialic acid-rich host receptors, a critical step in viral egress and propagation (see Influenza Mechanism). The rationale for use extends to translational oncology, where sialidase activity is implicated in cancer cell invasion and metastasis [see Mechanistic Insights].

Mechanism of Action of Oseltamivir acid

Oseltamivir acid is a potent, selective inhibitor of influenza neuraminidase (EC 3.2.1.18). It occupies the sialic acid binding pocket, mimicking the transition state and competitively blocking substrate access (APExBIO). This blockade prevents the enzymatic cleavage of α-Neu5Ac from newly formed virions, effectively trapping virus particles on the host cell surface and reducing viral spread (Influenza Neuraminidase Inhibitor). In vitro, Oseltamivir acid inhibits neuraminidase activity in a dose-dependent manner, typically with IC₅₀ values in the nanomolar range for both influenza A and B strains (Mechanistic Insights).

Evidence & Benchmarks

• Oseltamivir acid is rapidly generated from oseltamivir prodrug by carboxylesterase-mediated hydrolysis in the liver and intestine (Yang et al., 2025, DOI).
• In aqueous solutions, its solubility is ≥46.1 mg/mL with gentle warming; in DMSO, ≥14.2 mg/mL (APExBIO, product page).
• Oseltamivir acid inhibits sialidase activity and reduces cell viability in MDA-MB-231 and MCF-7 breast cancer cell lines in vitro, with effects enhanced by combinations with Cisplatin, 5-FU, Paclitaxel, Gemcitabine, or Tamoxifen (see Methods Table 1, site article).
• In RAGxCγ double mutant mice, intraperitoneal doses of 30–50 mg/kg inhibit tumor growth and metastasis; complete ablation of tumor progression is observed at higher doses (Yang et al., 2025, DOI).
• Resistance to Oseltamivir acid is primarily conferred by the H275Y mutation in the neuraminidase gene, which reduces binding affinity (Influenza Virus Fragment, site article).
• Humanized mouse models provide superior in vivo–in vitro correlation for carboxylesterase-activated prodrugs, such as oseltamivir (r = 0.98; Yang et al., 2025, DOI).

Applications, Limits & Misconceptions

Oseltamivir acid is primarily used for influenza antiviral research and as a benchmark tool for neuraminidase inhibitor screening. Its high solubility and stability profile make it suitable for in vitro and in vivo workflows. Recent evidence supports its use as an adjunct in breast cancer metastasis inhibition studies, where it reduces sialidase-mediated cell migration and invasion (see Mechanistic Insights). However, efficacy in clinical oncology remains investigational.

Common Pitfalls or Misconceptions

• Species differences: Rodent metabolic pathways differ from human, potentially affecting prodrug activation and requiring humanized mouse models for accurate translation (Yang et al., 2025).
• Direct antiviral activity: Only the active acid form (not the prodrug) exhibits direct neuraminidase inhibition in vitro.
• Resistance: The H275Y NA mutation significantly reduces Oseltamivir acid efficacy, making it unsuitable for such viral strains (see Resistance).
• Solution stability: Oseltamivir acid solutions are not stable for long-term storage and should be freshly prepared for experiments (APExBIO).
• Non-influenza viruses: Oseltamivir acid does not inhibit neuraminidases from non-influenza pathogens.

Workflow Integration & Parameters

For in vitro assays, Oseltamivir acid is typically dissolved in DMSO (≥14.2 mg/mL) or water (≥46.1 mg/mL with gentle warming) (see product page). Recommended storage is at -20°C; solutions should be prepared immediately before use to maintain stability. In cell-based assays, dose titration (e.g., 1–100 μM) is advised to determine IC₅₀ values for neuraminidase activity or cell viability endpoints. For in vivo studies, intraperitoneal administration at 30–50 mg/kg has been validated for anti-tumor efficacy in mouse xenograft models (Yang et al., 2025). Humanized mouse models are recommended for preclinical pharmacokinetic studies to recapitulate human carboxylesterase metabolism (see Mechanistic Insights). For influenza resistance studies, ensure viral strains are characterized for H275Y and related NA mutations.

This article updates and extends prior work by "Oseltamivir Acid: Mechanistic Insights and Strategic Path..." by providing a granular, evidence-based workflow for incorporating Oseltamivir acid into translational virology and oncology research, with a sharper focus on quantitative benchmarks and resistance parameters. For advanced translational context, see "Oseltamivir Acid at the Translational Frontier: Bridging ...", which offers a broader strategic view; this article delivers more atomic, parameterized data for direct protocol integration.

Conclusion & Outlook

Oseltamivir acid, as supplied by APExBIO, is a robust tool for studying influenza neuraminidase inhibition and for preclinical modeling of antiviral and adjunct cancer therapies. Its well-characterized mechanism, validated workflow parameters, and established resistance markers make it indispensable for antiviral drug development and mechanistic studies. The integration of humanized mouse models and resistance genotyping will enhance translational accuracy. As resistance mutations such as H275Y emerge, continued benchmarking and mechanistic elucidation are required to maintain Oseltamivir acid's role at the forefront of influenza and cancer research.